“We already mentioned in neuroscience that we see upside versus expectations for the migraine in Parkinson's [indiscernible] right now, what we see in consensus is peaking at below $4 billion. We've said several times, we expect them to each peak in excess of 5.”

How to check this claim

Look at: Peak annual sales (combined or individual, as disclosed) for the migraine (Qulipta/Ubrelvy franchise) and Parkinson's (e.g., ABBV-951/Vyalev) product lines

It came true if: Each franchise's disclosed peak annual sales figure exceeds $5 billion

Where: Company disclosures - earnings call commentary, investor presentations, or 10-K product revenue breakdowns

Verify independently

SEC filings for ABBV ↗ · Claim quote is verbatim from the 2026Q1 earnings call.